A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Squamous Cell Carcinoma Based on Nutritional Risk Screening Score (NRS2002)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A PHASE2 clinical study on Chemoradiotherapy and Esophageal Cancer, this trial is completed. The trial is conducted by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Nov 2023 — Jun 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Dec 2022 — Oct 2023 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .